Available online www.jocpr.com

Journal of Chemical and Pharmaceutical Research, 2023, 15(7):17-18

Opinion Article

ISSN : 0975-7384
CODEN(USA) : JCPRC5

Optimizational Studies of Salbutamol Sulphate Mucoadhesive Buccal Patches

Jane Carroll*

Department of Pharmacy, University of Toronto, Ontario, Canada

Received: *26-Jun-2023, Manuscript No. JOCPR-23-108445;* ***Editor assigned:*** *29-Jun-2023, PreQC No. JOCPR-23-108445(PQ);* ***Reviewed:*** *12-Jul-2023, QC No. JOCPR-23-108445;* ***Revised:*** *21-Jul-2023, Manuscript No. JOCPR- 23-108445(R);* ***Published:*** *28-Jul-2023, DOI:10.37532/0975-7384.2023.15(7).044.*

DESCRIPTION

Designing and evaluating mucoadhesive buccal patches of Salbutamol Sulphate is a complex process. The study is produce an effective, safe and reliable delivery method for this asthma medication, enabling it to be administered through the buccal cavity and absorbed directly into the bloodstream. The first stage of design is to determine the appropriate formulation for the patch. The drug, Salbutamol Sulphate, needs to be combined with a bioadhesive polymer such as Hydroxypropyl Methyl Cellulose (HPMC). This will help it adhere to the mucosal surfaces and increase its retention time, allowing the drug to be released gradually over an extended period. The proportion of drug and bioadhesive material must be carefully optimized to ensure sufficient dosage delivery, yet not compromise the patch's adhesion properties.

Excipients such as plasticizers may also be included in the formulation to enhance the flexibility of the patch and improve patient comfort. The selection of plasticizer should be based on its compatibility with the polymer and drug, and its impact on the overall drug release profile. Once the formulation is determined, the patches are prepared by solvent casting method. The polymer, drug, and plasticizer are dissolved in a suitable solvent and cast into a mold to form patches of a specific size and thickness. The patches are then allowed to dry at room temperature. The evaluation of the patches involves assessing several important properties. Firstly, the physical properties of the patches such as thickness, weight, and surface pH are checked. Variability in these characteristics can affect drug release and adhesion, so they need to be consistent across all patches.

The mucoadhesive properties of the patches are evaluated. This involves measuring the detachment force required to remove the patch from a mucosal surface. A balance must be struck between providing strong adhesion to improve drug delivery and ensuring easy removal when necessary. Drug release studies are carried out to determine how much Salbutamol Sulphate is released over time. The aim is to formulate a patch that provides a consistent, controlled release of the drug, usually over a period of several hours. Dissolution studies can be conducted in artificial saliva to simulate the buccal environment. Stability studies are also performed to ensure the patches maintain their effectiveness and safety over their intended shelf life. They are stored under different temperature and humidity conditions, and periodically checked for changes in physical appearance, drug content, and drug release.

In vitro and *in vivo* studies provide further evidence of the patch's effectiveness. *In vitro* studies involve testing the patches on animal mucosa or human buccal epithelial cells, while *in vivo* studies involve administering the patches to suitable animal models or human volunteers and monitoring the drug's absorption and effects. The design and evaluation of mucoadhesive buccal patches of Salbutamol Sulphate provide several advantages like buccal administration bypasses the first-pass metabolism that occurs in the liver after oral administration. This can significantly increase the bioavailability of the drug. These patches are designed to provide a consistent, controlled release of Salbutamol Sulphate over time, maintaining optimal drug levels in the bloodstream. This minimizes the risk of peaks and troughs associated with repeated dosing and improves treatment efficacy. Buccal patches are generally more comfortable and convenient than other routes of administration, such as injections or inhalation. They are easy to apply, non-invasive, and do not interfere with patient's normal activities. This can greatly improve patient compliance.

The patches can be designed to accommodate a wide range of drugs, not just Salbutamol Sulphate, potentially expanding their applications in medication delivery. Drugs in buccal patches are typically stable at room temperature and have a reasonable shelf life. Since the drug bypasses the stomach, it can reduce the risk of gastric side effects that are common with oral administration. While these advantages highlight the potential benefits of this drug delivery system, it is crucial to note that the success of buccal patches also depends on the drug's characteristics, formulation design, and patient's individual health conditions. Therefore, comprehensive design, evaluation, and clinical trials are necessary to confirm their effectiveness and safety.

In conclusion, the design and evaluation of mucoadhesive buccal patches of Salbutamol Sulphate is a multi-stage process that requires careful formulation design, meticulous preparation, and comprehensive evaluation to ensure the patches are effective, safe, and comfortable for patients to use. With this innovative drug delivery system, patients can potentially enjoy the benefits of convenient and efficient administration of Salbutamol Sulphate, significantly improving their quality of life.